摘要
目的 探讨辛芩颗粒联合氯雷他定用于变应性鼻炎的临床评价及对血清酸性粒细胞（EOS）、集落刺激因子（GSF）、肿瘤坏死因子（TNF）-α水平的影响。方法 选择2014年1月~2016年11月我院接诊的90例变应性鼻炎患者,通过随机数表法分为观察组（n=45）和对照组（n=45）。对照组给予氯雷他定治疗,观察组联合辛芩颗粒治疗。比较2组血清EOS、CSF、TNF-α水平、症状积分、临床疗效及不良反应。结果 治疗后,观察组血清EOS、CSF、TNF-α水平均明显低于对照组（P〈0.05）;观察组症状积分明显低于对照组（P〈0.05）;观察组临床疗效总有效率明显高于对照组[93.33%（42/45）vs.73.33%（33/45）]（P〈0.05）;2组不良反应发生率比较差异无统计学意义。结论 在变应性鼻炎中应用辛芩颗粒联合氯雷他定效果显著,可有效降低血清EOS、CSF、TNF-α水平,缓解临床症状。
Objective To study clinical evaluation of xinqin granule combined with loratadine in treatment of allergic rhinitis and its effects on serum eosinophil（ EOS） , colony stimulating factor （ CSF） and tumor necrosis factor（ TNF）-α. Methods 90 patients of allergic rhinitis who received therapy from January 2014 to November 2016 in our hospital were selected. According to random number table, those patients were divided into the observation group （ n, = 45 ） and the control group （ n, = 45 ）. The control group was treated with loratadine, while the observation group was combined with xinqin granule. Then the serum EOS, CSF and TNF-a, symptom score, clinical efficacy and adverse reactions were compared. Results After treatment, the serum levels of EOS, CSF and TNF-ain the observation group were significantly lower than that of the control group（P 〈 0. 05 ） ; the symptom score in the observation group was significantly lower than that of the control group （P 〈0. 05） ; the total effective rate in the observation group was significantly higher than that of the control group[93. 33% （42/45） vs. 73. 33% （33/45） ] （P 〈0. 05） ; there was no significant difference in the incidence of adverse reactions between the two groups. Conclusion Xinqin granule combined with loratadine is well for allergic rhinitis, which can effectively reduce serum levels of EOS, CSF, TNF-α, relieve clinical symptoms, it5 s worthy of application and promotion.
出处
《中国生化药物杂志》
CAS
2017年第4期81-83,共3页
Chinese Journal of Biochemical Pharmaceutics
